Cargando…

Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service—Utilising cerebrospinal fluid biomarkers and appropriate use criteria

OBJECTIVES: Aducanumab is a monoclonal antibody which has recently been licenced for use by the food and drug administration for treatment of patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia. Appropriate use criteria (AUC) for Aducanumab in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Togher, Zara, Dolphin, Helena, Russell, Caoimh, Ryan, Marie, Kennelly, Séan P., O'Dowd, Séan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542503/ https://www.ncbi.nlm.nih.gov/pubmed/35861223 http://dx.doi.org/10.1002/gps.5789

Ejemplares similares

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

An Update on Apathy in Alzheimer’s Disease
por: Dolphin, Helena, et al.
Publicado: (2023)

“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
por: Padovani, Alessandro, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Primary medical care in Irish prisons
por: Barry, Joe M, et al.
Publicado: (2010)

Reliability of the isometric mid-thigh pull peak force in Irish schoolboy rugby players
por: Hill, D O’Dowd, et al.
Publicado: (2021)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

A method for discovering and inferring appropriate eligibility criteria in clinical trial protocols without labeled data
por: Restificar, Angelo, et al.
Publicado: (2013)

Do specialist pulmonologists appropriately utilise thoracic surgery for drug-resistant pulmonary tuberculosis? A survey
por: Alexander, G, et al.
Publicado: (2018)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

The criteria of eligibility to the extracorporeal treatment
por: Zangrillo, A
Publicado: (2012)

Bed Utilisation in an Irish Regional Paediatric Unit – A Cross-Sectional Study Using the Paediatric Appropriateness Evaluation Protocol (PAEP)
por: ÓhAiseadha, Coilín, et al.
Publicado: (2016)

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
por: Dickson, Samuel P., et al.
Publicado: (2023)

The impact of the COVID-19 pandemic on patient complaints within one Irish teaching hospital
por: O’Dowd, Emily, et al.
Publicado: (2023)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Epilepsy surgery: eligibility criteria and presurgical evaluation
por: Ryvlin, Philippe, et al.
Publicado: (2008)

Analysis of Eligibility Criteria Complexity in Clinical Trials
por: Ross, Jessica, et al.
Publicado: (2010)

“The Wandering Nerve Linking Heart and Mind” – The Complementary Role of Transcutaneous Vagus Nerve Stimulation in Modulating Neuro-Cardiovascular and Cognitive Performance
por: Dolphin, Helena, et al.
Publicado: (2022)

Safety and feasibility of transcutaneous vagus nerve stimulation in mild cognitive impairment: VINCI-AD study protocol
por: Dolphin, Helena, et al.
Publicado: (2023)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

A review of research on eligibility criteria for clinical trials
por: Su, Qianmin, et al.
Publicado: (2023)

Assessment of Uptake Appropriateness of Computed Tomography for Lung Cancer Screening According to Patients Meeting Eligibility Criteria of the US Preventive Services Task Force
por: Liu, Yu, et al.
Publicado: (2022)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_848osr3itt3bjmqae5ip5qm32v